【Abstract】 Objective To study the effects of tigrine on platelet inhibition and major cardiac adverse events in patients with acute coronary syndromes (ACS). Methods Between September 2014 and December 2015, 51 patients with acute coronary syndrome patients with ACS underwent PCI treated with tricloprid and were selected as observation group. In the same period, 51 patients with ACS underwent PCI treated with clopidogrel were selected as a control group. The ADPinduced platelet inhibition rate, the incidence of major adverse cardiac events and bleeding and difficulty in breathing rate were observed. Results The platelet inhibition rate of the observation group was significantly higher than that of the control group at 1 week and 1 month after treatment. The difference was significant (P＜005). Major adverse cardiac events in observation group were significantly less than that in the control group. The difference was significant (P＜005). Conclusion The effect of ticagrelor for ACS patients underwent PCI is significant. The incidence of major cardiac adverse events is reduced and the safety is good.